Mahboobeh joined Roche Molecular Diagnostics in Feb 2016, as Director of Clinical Sciences for the cervical cancer team. In this role, she co-led the IMproving Primary screening And Colposcopy Triage (IMPACT) trial, one of the largest cancer screening trials at Roche. Combining efforts and products across Roche Molecular Diagnostics and Roche Tissue Diagnostics, the team demonstrated the clinical validity of an entire disease-specific portfolio in cervical cancer screening involving molecular testing for HPV for primary screening, tissue based assays (CINtec PLUS Cytology) for managing women with positive HPV test results, and for diagnosis (CINtec Histology). Results from the IMPACT trial led to FDA approvals of high throughput cobas HPV test and CINtec PLUS Cytology which are now commercially available. Before joining Roche, she worked at the US National Cancer Institute where she researched HPV infection and cervical cancer natural history, screening and immune response to HPV natural infection and vaccination.